Synergistic Implantable Biotherapeutic Agent Delivery Systems

Publication ID: 24-11857672_0003_PTD

Published: October 28, 2025

Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Synergistic Implantable Biotherapeutic Agent Delivery Systems,” Published Technical Disclosure No. 24-11857672_0003_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857672_0003_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,672.

Summary of the Inventive Concept

A novel system integrating nanoporous implantable canisters with AI, IoT, blockchain, and novel materials to enable real-time monitoring, personalized treatment planning, and secure data management for biotherapeutic agent delivery and tissue repair.

Background and Problem Solved

The original patent disclosed a metallic, nanoporous device for encapsulating cellular and biotherapeutic agents. However, it lacked the ability to monitor and adjust agent release in real-time, and secure data management. The new inventive concept addresses these limitations by integrating the nanoporous canister with AI-powered biosensors, IoT-enabled sensors, blockchain-based data storage, and novel materials to create a more powerful system.

Detailed Description of the Inventive Concept

The synergistic system comprises a nanoporous implantable canister, an AI-powered biosensor for real-time monitoring of agent release and tissue repair, IoT-enabled sensors for monitoring and adjusting canister performance, and a blockchain-based data storage platform for secure and transparent data management. The canister body is made from a novel, biocompatible nanomaterial integrated with a microfluidic channel for controlled agent release. The system enables real-time monitoring, personalized treatment planning, and secure data management, thereby promoting more effective tissue repair.

Novelty and Inventive Step

The new claims introduce the integration of AI, IoT, blockchain, and novel materials with the nanoporous implantable canister, which is not obvious from the original patent. The synergistic combination of these technologies enables real-time monitoring, personalized treatment planning, and secure data management, which is not achievable by the original patent.

Alternative Embodiments and Variations

Alternative embodiments include using different AI algorithms, IoT sensor configurations, or blockchain platforms. Variations of the system could include integrating with wearable devices, using different nanomaterials, or incorporating additional diagnostic tools.

Potential Commercial Applications and Market

The synergistic system has significant commercial potential in the fields of regenerative medicine, tissue engineering, and personalized healthcare. The market for biotherapeutic agent delivery systems is growing rapidly, and this inventive concept is poised to capture a significant share by offering a more effective and secure solution.

CPC Classifications

Section	Class	Group
A	A61	A61K9/0024
A	A61	A61F2/022
A	A61	A61K31/337
A	A61	A61K31/397
A	A61	A61K31/436
A	A61	A61K31/65
A	A61	A61K31/7036
A	A61	A61K35/28
A	A61	A61K38/14
A	A61	A61K38/1866
A	A61	A61K38/22
A	A61	A61K39/395
A	A61	A61K47/02
A	A61	A61M39/0247
A	A61	A61M2039/027
A	A61	A61M2039/0261
A	A61	A61M2039/0276
A	A61	A61M2205/04

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Biomedical engineering, specifically implantable medical devices for cellular and biotherapeutic agent delivery, with expertise in nanomaterials, biosensors, and medical data management technologies

Person of Ordinary Skill (PHOSITA) Profile

A biomedical engineer with advanced degrees in bioengineering or medical device design, familiar with nanoporous materials, cellular delivery systems, and emerging digital health technologies, with knowledge of medical device integration and data management platforms

Obviousness Rationale

A person of ordinary skill would recognize that integrating digital monitoring and management technologies with existing implantable medical devices represents a predictable extension of current biomedical engineering practices. The source patent's nanoporous implantable device provides a clear foundation for incorporating advanced sensing and data management technologies. The proposed variations represent logical combinations of known technologies in medical device design and digital health monitoring.

Obvious Combinations & Variations

Source Patent Element

Nanoscale through-porous structure for cellular and biotherapeutic agent delivery

PTD Variation

Integration of AI-powered biosensors and microfluidic channels for real-time monitoring of agent release

Obviousness Reasoning

Adding sensor technologies to implantable medical devices is a known technique for improving patient monitoring and treatment efficacy, representing a predictable application of existing digital health technologies

Source Patent Element

Implantable medical device for isolating therapeutic agents

PTD Variation

Blockchain-based data storage platform for secure management of device performance and patient data

Obviousness Reasoning

Implementing secure data management systems for medical devices is a standard approach in digital health, with blockchain representing a predictable technological solution for data security and transparency

Source Patent Element

Biocompatible nanoporous device for cellular delivery

PTD Variation

IoT-enabled sensors for real-time monitoring and adjustment of canister performance

Obviousness Reasoning

Incorporating Internet of Things (IoT) technologies into medical devices is a well-established trend in personalized medicine, representing a finite and predictable solution for improving device monitoring

Source Patent Element

Implantable device for tissue repair

PTD Variation

AI-powered diagnostic platform using machine learning to predict optimal treatment plans

Obviousness Reasoning

Applying machine learning to medical device data is a known technique for improving treatment outcomes, representing a logical extension of existing medical diagnostic technologies

35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857672 and the principles of obviousness under 35 U.S.C. § 103, the proposed variations in the published technical disclosure would be considered obvious to a person having ordinary skill in the art of biomedical device design. The combination of nanoporous implantable device technologies with digital monitoring and management systems represents a predictable application of known techniques in medical device engineering, thereby rendering potential claims to such variations unpatentable as obvious modifications of the prior art.

Original Patent Information

Patent Number	US 11,857,672
Title	Implantable cellular and biotherapeutic agent delivery canister
Assignee(s)	NanoVault Medical LLC